Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-11,300
Closed -$3.25M 85
2023
Q4
$3.25M Sell
11,300
-36,000
-76% -$9.81M 0.1% 275
2023
Q3
$12.7M Buy
47,300
+35,400
+297% +$8.83M 0.42% 44
2023
Q2
$2.64M Sell
11,900
-3,500
-23% -$812K 0.07% 319
2023
Q1
$3.72M Buy
15,400
+9,200
+148% +$2.26M 0.13% 207
2022
Q4
$1.63M Buy
+6,200
New +$1.66M 0.07% 360

Other funds holding AMGN

Point72 Middle East FZE's AMGN Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Amgen (AMGN) in Q1 2024, closing a stake of 31,082 shares — an estimated $8.95M sold.

Point72 Middle East FZE first reported a position in AMGN in Q4 2022 and held it in 3 quarters. The position peaked at $8.95M in Q4 2023. 2,715 funds tracked by Wall St. Rank hold AMGN as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Amgen position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 31,082 Amgen shares in Q1 2024, an estimated $8.95M.
  • Point72 Middle East FZE first reported a position in Amgen in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Amgen position peaked at $8.95M in Q4 2023.
  • 2,715 funds tracked by Wall St. Rank held Amgen as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.